Literature DB >> 21954833

Original article anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury.

Hongyan Liu1, Steven J McTaggart, David W Johnson, Glenda C Gobe.   

Abstract

BACKGROUND AIMS: Ischemia-reperfusion (IR) injury is a common cause of acute renal failure. Bone marrow (BM)-derived mesenchymal stromal cells (MSC) delivered after renal IR are renoprotective, but knowledge of the protective mechanism is still in development. This investigation analyzed the protective molecular mechanisms of MSC, in particular relating to modulated oxidative stress.
METHODS: In vivo and in vitro models of renal IR were analyzed with and without MSC. In vivo, adult male Sprague-Dawley rats were subjected to 40-min unilateral renal IR. Rat BM-derived MSC were administered at 24 h post-IR (IR + MSC). Other groups had IR but no MSC, or MSC but no ischemia (all groups n = 4). Apoptosis, inflammation, oxidative stress and reparative signal transduction molecules or growth factors were studied 4 days post-IR. In vitro, protection by MSC against oxidative stress (0.4 mm hydrogen peroxide) was investigated using rat renal tubular epithelial cells (NRK52E) with or without MSC in co-culture (tissue culture trans-well inserts), followed by similar analyses to the in vivo investigation.
RESULTS: In vivo, kidneys of IR + MSC animals had significantly increased cell proliferation/regeneration (cells positive for proliferating cell nuclear antigen, expression of epidermal growth factor), increased heme-oxygenase-1 (improved cell survival, anti-oxidant) and decreased 8-OHdG (decreased oxidative stress). In vitro, MSC delivered with oxidative stress significantly decreased apoptosis and Bax (pro-apoptotic protein), and increased mitosis and phospho-ERK1/2, thereby minimizing the damaging outcome and maximizing the regenerative effect after oxidative stress.
CONCLUSIONS: The benefits of MSC, in IR, were primarily pro-regenerative, sometimes anti-apoptotic, and novel anti-oxidant mechanisms were identified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21954833     DOI: 10.3109/14653249.2011.613927

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  20 in total

Review 1.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

Review 2.  In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury.

Authors:  Danilo C de Almeida; Cassiano Donizetti-Oliveira; Priscilla Barbosa-Costa; Clarice St Origassa; Niels Os Câmara
Journal:  Clin Biochem Rev       Date:  2013-11

Review 3.  Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology.

Authors:  Norberto Perico; Federica Casiraghi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-11-30       Impact factor: 10.121

4.  Differential reduction of reactive oxygen species by human tissuespecific mesenchymal stem cells from different donors under oxidative stress.

Authors:  Swati Paliwal; Anupama Kakkar; Rinkey Sharma; Balram Airan; Sujata Mohanty
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

5.  Acute lung injury induced by acute uremia and renal ischemic-reperfusion injury: The role of toll-like receptors 2 and 4, and oxidative stress.

Authors:  Seyedeh-Sara Hashemi; Sahar Janfeshan; Zeinab Karimi
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

6.  Breast milk mesenchymal stem cells abate cisplatin-induced cardiotoxicity in adult male albino rats via modulating the AMPK pathway.

Authors:  Mahitab M Nageeb; Sara F Saadawy; Seba Hassan Attia
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

7.  In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

Authors:  Abdelrhman Abumoawad; Ahmed Saad; Christopher M Ferguson; Alfonso Eirin; Sandra M Herrmann; LaTonya J Hickson; Busra B Goksu; Emily Bendel; Sanjay Misra; James Glockner; Allan B Dietz; Lilach O Lerman; Stephen C Textor
Journal:  Kidney Int       Date:  2019-12-13       Impact factor: 10.612

Review 8.  Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.

Authors:  S Suvakov; C Richards; V Nikolic; T Simic; K McGrath; A Krasnodembskaya; L McClements
Journal:  Curr Hypertens Rep       Date:  2020-04-14       Impact factor: 5.369

Review 9.  Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears.

Authors:  Fernando Ezquer; Jaime Gutiérrez; Marcelo Ezquer; Christian Caglevic; Helio C Salgado; Sebastián D Calligaris
Journal:  Stem Cell Res Ther       Date:  2015-06-24       Impact factor: 6.832

10.  Effect of an omega-3 lipid emulsion in reducing oxidative stress in a rat model of intestinal ischemia-reperfusion injury.

Authors:  Atsuhiro Arisue; Naoki Shimojima; Masayuki Tomiya; Takayuki Shimizu; Daisuke Harada; Mitsuo Nakayama; Hirofumi Tomita; Masahiro Shinoda; Minoru Tanabe; Ikuro Maruyama; Masaru Mizuno; Tatsuo Kuroda; Go Wakabayashi; Yasuhide Morikawa
Journal:  Pediatr Surg Int       Date:  2012-09       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.